Prognostic Impact of Human Lymphocyte Antigen (HLA) Class I Expression in Patients With Breast Cancer.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-09-01 DOI:10.21873/anticanres.17233

Motonobu Uchiyama, Hiroaki Shima, Goro Kutomi, Daisuke Kyuno, Asaka Wada, Yoko Kuga, Yasuaki Tamura, Yoshihiko Hirohashi, Toshihiko Torigoe, Ichiro Takemasa

{"title":"Prognostic Impact of Human Lymphocyte Antigen (HLA) Class I Expression in Patients With Breast Cancer.","authors":"Motonobu Uchiyama, Hiroaki Shima, Goro Kutomi, Daisuke Kyuno, Asaka Wada, Yoko Kuga, Yasuaki Tamura, Yoshihiko Hirohashi, Toshihiko Torigoe, Ichiro Takemasa","doi":"10.21873/anticanres.17233","DOIUrl":null,"url":null,"abstract":"Background/aim: Various biomarkers are utilized in the field of breast cancer. Human lymphocyte antigen (HLA) class I molecules have a critical role in cancer immune surveillance. Therefore, this study aimed to assess the HLA class I expression and analyze the correlation with clinicopathologic factors in breast cancer.Patients and methods: We investigated the clinical pathology archives of 150 consecutive patients with breast cancer who underwent a curative operation at the Sapporo Medical University, Japan, from January 2012 to December 2014. Immunohistochemical staining was used to evaluate HLA class I expression and CD8-positive T cell infiltration. The Pearson χ2 test was used to assess HLA class I expression level and clinicopathological parameters. The Kaplan-Meier method was used to evaluate survival and the log-rank test to analyze the differences between survival curves.Results: Patients with dull/negative HLA class I had significantly poor disease-free survival (DFS) compared with those with positive HLA class I (p=0.0073). Univariate analyses revealed that pT, pN, positive lymphatic invasion, and dull/negative HLA class I were significantly associated with DFS. Multivariate analyses revealed dull/negative HLA class I as an independent poor prognostic factor (hazard ratio=2.75, 95% confidence interval=1.30-5.80, p=0.008).Conclusion: HLA class I expression level may have a very sensitive prognostic effect on patients with breast cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17233","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Various biomarkers are utilized in the field of breast cancer. Human lymphocyte antigen (HLA) class I molecules have a critical role in cancer immune surveillance. Therefore, this study aimed to assess the HLA class I expression and analyze the correlation with clinicopathologic factors in breast cancer.

Patients and methods: We investigated the clinical pathology archives of 150 consecutive patients with breast cancer who underwent a curative operation at the Sapporo Medical University, Japan, from January 2012 to December 2014. Immunohistochemical staining was used to evaluate HLA class I expression and CD8-positive T cell infiltration. The Pearson χ² test was used to assess HLA class I expression level and clinicopathological parameters. The Kaplan-Meier method was used to evaluate survival and the log-rank test to analyze the differences between survival curves.

Results: Patients with dull/negative HLA class I had significantly poor disease-free survival (DFS) compared with those with positive HLA class I (p=0.0073). Univariate analyses revealed that pT, pN, positive lymphatic invasion, and dull/negative HLA class I were significantly associated with DFS. Multivariate analyses revealed dull/negative HLA class I as an independent poor prognostic factor (hazard ratio=2.75, 95% confidence interval=1.30-5.80, p=0.008).

Conclusion: HLA class I expression level may have a very sensitive prognostic effect on patients with breast cancer.

查看原文本刊更多论文

乳腺癌患者人类淋巴细胞抗原 (HLA) I 类表达的预后影响

背景/目的：乳腺癌领域使用了多种生物标记物。人类淋巴细胞抗原（HLA）I类分子在癌症免疫监视中起着至关重要的作用。因此，本研究旨在评估 HLA I 类分子的表达，并分析其与乳腺癌临床病理因素的相关性：我们调查了 2012 年 1 月至 2014 年 12 月期间在日本札幌医科大学接受治愈性手术的 150 名连续乳腺癌患者的临床病理档案。免疫组化染色用于评估 HLA I 类表达和 CD8 阳性 T 细胞浸润。皮尔逊χ2检验用于评估HLA I类表达水平和临床病理参数。采用Kaplan-Meier法评估生存率，并用log-rank检验分析生存曲线之间的差异：结果：与HLA I级阳性患者相比，HLA I级阴性患者的无病生存率（DFS）明显较低（P=0.0073）。单变量分析显示，pT、pN、淋巴侵袭阳性和HLA I级阴性与无病生存期显著相关。多变量分析显示，HLA I级阴性/迟钝是一个独立的不良预后因素（危险比=2.75，95%置信区间=1.30-5.80，P=0.008）：结论：HLA I类表达水平可能对乳腺癌患者的预后有非常敏感的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.